• Subject is at least 18 years old

• Subject (or legal guardian) understands the trial requirements and treatment procedures and provides written informed consent prior to any trial-specific tests or treatment

• Patient with an indication for PCI due to suspected in-stent restenosis

• Non-target lesion PCI are allowed in non-target vessels to be treated with approved interventional devices prior to randomization as follows:

⁃ Angiographic Inclusion Criteria:

• In-stent restenosis after drug-eluting stent implantation(s) in the target lesion (i.e. single and multiple stent layer ISR cases are eligible)

• Target lesion must have visually estimated stenosis ≥50% and less than 100% diameter stenosis in symptomatic patients; or a visually estimated target lesion diameter stenosis of ≥70%, or by evidence of ischemia by coronary physiology (fractional flow reserve \[FFR\] ≤0.80 or non-hyperemic pressure ratio \[NHPR\] ≤0.89) in absence of symptoms

• Successful lesion preparation (residual stenosis \<30%), without complications (no or slow flow, flow-limiting dissection, perforation, distal embolization) and without plan for stenting

• Target lesion in a native coronary artery

• Thrombolysis In Myocardial Infartction (TIMI) grade flow ≥1 in target lesion

• Target reference vessel diameter (visual estimation) \>2.0 and ≤4.0 mm

• Target lesion length (including tandem lesions) ≤36.0 mm (visual estimation) and can be covered by only one balloon

• One ISR target lesion (overlapping stents are allowed) to be treated per patient and in single major coronary artery or side branch (reference vessel diameter \>2.0 mm)

• Other coronary lesions (ISR or non-ISR) in non-target vessel are allowed and may be treated by any approved interventional device, but must be treated successfully prior to randomization